Ex-Lilly U.S. chief Enrique Conterno takes FibroGen helm ahead of key drug launch
admin 6th January 2020 Uncategorised 0After last year’s unexpected passing of founder and long-time helmsman Thomas Neff, FibroGen needed a permanent successor—and with its big roxadustat launch looming, that new CEO would ideally know the ropes in kidney and metabolic diseases. Now, it’s found a
read more